Agenus Inc. (AGEN)

NCM – Real Time Price. Currency in USD

3.44

+0.18 (5.52%)

At close: May 12, 2026, 4:00 PM EDT

3.44

0.00 (0.00%)

After-hours: May 12, 2026, 7:55 PM EDT

06.05.2026

Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?

Here is how Agenus (AGEN) and Align Technology (ALGN) have performed compared to their sector so far this year.

04.05.2026

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its first quarter 2026 financial results before the market opens on Monday, May 11, 2026. Agenus plans to host a webcast in June, in conjunction with its Annual Meeting of Shareholders, to spotlight key strategic priorities, upcoming data milestones, and progress across the global botensilimab (BOT) and balstilimab (BAL) development program. About.

04.05.2026

Agenus (AGEN) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Agenus (AGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

29.04.2026

Bio-Techne's Q3 Earnings on Deck: What's in Store for the Stock?

TECH gears up for Q3 results with modest revenue growth expected as biotech funding trends and product momentum shape the outlook.

28.04.2026

Here's How Henry Schein Is Placed Ahead of Q1 Earnings

HSIC heads into Q1 earnings results with steady estimates, a 5.1% revenue growth outlook and strength across distribution, specialty products and tech.

23.04.2026

Here's Why Agenus (AGEN) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

21.04.2026

Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AI--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that four abstracts highlighting botensilimab (BOT), alone or in combination with balstilimab (BAL), have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29–June 2, 2026, in Chicago, Illinois. The accepted abstracts reflect continued progress of Agenus' botensilimab and balstilimab immunotherapy program ac.

Videos

No Data

There is no data to display

Press releases

04.05.2026

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

21.04.2026

Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

LEXINGTON, Mass. & MARLOW, England--(BUSINESS WIRE)---- $AGEN #AAC--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, and BAP Pharma, a global medicines access and clinical trial supply company, today announced the exclusive appointment of BAP Pharma as Agenus' global partner for botensilimab (BOT) plus balstilimab (BAL) authorized global access programs. The partnership supports compliant, patient-focused access to BOT+BAL through authorized pathways where permitted by local regulations. Ef.

$Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer$

17.04.2026

Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AACR2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced data from an investigator-initiated Phase II trial at Memorial Sloan Kettering Cancer Center, investigating botensilimab (BOT) and balstilimab (BAL) in combination with agenT-797, MiNK's allo-iNKT cell therapy, ramucirumab and paclitaxel in patients with advanced PD-1 refractory gastroesophageal adenocarcinoma. The data are being presented at the American Association for Cancer.

$Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026$

03.04.2026

Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AACR2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that data from an investigator-initiated Phase II trial conducted at Memorial Sloan Kettering Cancer Center will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22, 2026, in San Diego, CA. The study evaluates botensilimab (BOT) and balstilimab (BAL) in combination with agenT-797, an allogeneic iNKT cell therapy developed.

Agenus Inc. (AGEN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Agenus Inc. (AGEN)

Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

Agenus (AGEN) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Bio-Techne's Q3 Earnings on Deck: What's in Store for the Stock?

Here's How Henry Schein Is Placed Ahead of Q1 Earnings

Here's Why Agenus (AGEN) is a Strong Momentum Stock

Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026

Videos

No Data

Press releases

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer

Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

Agenus (AGEN) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Bio-Techne's Q3 Earnings on Deck: What's in Store for the Stock?

Here's How Henry Schein Is Placed Ahead of Q1 Earnings

Here's Why Agenus (AGEN) is a Strong Momentum Stock

Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026

Videos

No Data

Press releases

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer

Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

Search stocks

Agenus Inc. (AGEN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Agenus Inc. (AGEN)

Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

Agenus (AGEN) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Bio-Techne's Q3 Earnings on Deck: What's in Store for the Stock?

Here's How Henry Schein Is Placed Ahead of Q1 Earnings

Here's Why Agenus (AGEN) is a Strong Momentum Stock

Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026

Videos

No Data

Press releases

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer

Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

Agenus (AGEN) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Bio-Techne's Q3 Earnings on Deck: What's in Store for the Stock?

Here's How Henry Schein Is Placed Ahead of Q1 Earnings

Here's Why Agenus (AGEN) is a Strong Momentum Stock

Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026

Videos

No Data

Press releases

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer

Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026